Properties of 3-(1-Phenyl-Propyl)-4-Oxycoumarin (Marcoumar®) in the Plasma when Tested in Normal Cases and under the Influence of Drugs

K Seiler; F Duckert

doi:10.1055/s-0038-1651217

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1968; 19(03/04): 389-396
DOI: 10.1055/s-0038-1651217

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Properties of 3-(1-Phenyl-Propyl)-4-Oxycoumarin (Marcoumar®) in the Plasma when Tested in Normal Cases and under the Influence of Drugs

Authors

K Seiler

¹Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the Department of Medicine (Head: Prof. Dr. F. Koller) of the University, Basel, Switzerland
F Duckert

¹Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the Department of Medicine (Head: Prof. Dr. F. Koller) of the University, Basel, Switzerland

Abstract

Summary

A fluorimetric method served to determine Marcoumar in blood plasma. The biological half-time of Marcoumar after an administration of 2.2 mg/10 kg is 6½ days. Variations in maintenance dose requirements seem not to be primarly determined by differences in absorption or excretion of the anticoagulant drug. In therapeutical concentrations about 99% of the drug are bound to plasma protein. Marcoumar can be displaced in vitro from plasma protein by different drugs. The anticoagulant effect is not increased in every case in which the anticoagulant is displaced in plasma from its protein binding.

Volltext

Referenzen

References
1 Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar [3-(l’-Phenyl-propyl)-4-oxy-cumarin] und seinen Antagonisten Konakion (synthetisches Vitamin K₁). Schweiz. med. Wschr. 1953; 83 (20) 471
2 Koller F, Jakob H. Über ein neues, hochaktives Antikoagulans mit protrahierter Wirkung (Marcoumar). Schweiz. med. Wschr. 1953; 83 (20) 476
3 Deutsch E, Hueber E.F, Mayer E, Wohlrab K. Über die Verwendung eines neuen Antikoagulans. Marcoumar, zur Therapie. Klin. Med. 1954; 2: 49
4 Hofstetter J. Bestimmungsmethode für Marcoumar in Blut-Plasma. Personal communication.
5 O’Reilly R.A, Aggeler P.M, Hoag M.S, Leong L. Studies on coumarin anticoagulant drugs: assay of warfarin and its biologic application. Thrombos. Diathes. haemorrh. (Stuttg.) 1962; 5: 82
6 Feigl F. Test through conversion into fluorescing alkali salt of o-hydroxycinnamic acid. J. Amer. chem. Soc. 1955; 77: 4162
7 Dettli L, Spring P. Pharmakokinetik der Chemotherapeutika: Theorie und Praxis. Regensburg. Jb. ärztl. Fortbild. 1966; 14: 17
8 Aggeler P. M, O’Reilly R. A. The pharmacological basis of oral anticoagulant therapy. In: Pathogenesis and Treatment of thromboembolic Diseases. Internat. Symposium Basle. ed Koller F, Duckert F, Streuli F, Schattauer F. K. Stuttgart 1965
9 Douglas A.S. Anticoagulant therapy. Blackwell Scientific Publications; Oxford: 1962
10 Anton A.H. The relation between the binding of sulfonamides to albumin and their antibacterial efficacy. J. Pharmacol. exp. Ther. 1960; 129: 282
11 Anton A.H. A drug-induced change in the distribution and renal excretion of sulfonamides. M. Pharmacol. exp. Therap. 1961; 134: 291
12 Newbould B.B, Kilpatrick R. Long-acting sulphonamides and protein-binding. Lancet 1960; I: 887
13 Aggeler P.M, O’Reilly R.A, Leong L, Kowitz P.E. Potentiation of anticoagulant effect of Warfarin by phenylbutazone. New Engl. J. Med. 1967; 276: 496
14 Ghristensen L.K, Hansen J.M, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide treated diabetics. Lancet 1963; II: 1298
15 Kristensen M, Hansen J.M, Hellerup D. Potentiation of the tolbutamide effect by dicoumarol. Diabetes 1967; 16: 211
16 Thorp J.M. The influence of plasma proteins on the action of drugs. Absorption and Distribution of Drugs. Binns, T.B., E.S. Livingstone 1964